Enterra Medical

Enterra Medical

Develops implantable gastric electrical stimulation therapy

Overview

Enterra Medical develops the Enterra Therapy system, a gastric electrical stimulation implant for adults with drug-refractory gastroparesis. The system includes a small implant in the lower abdomen and two leads placed into the stomach wall; it sends mild electrical pulses to stomach muscles and nerves and can be adjusted by a physician using an external programmer, with the option to turn off or remove the device. Its approach centers on this specific therapy with ongoing improvements (such as the Enterra II MR Conditional system and the Enterra ReliaStim lead) and collaboration with Medtronic as an operational partner. The goal is to provide a safe, adjustable, and reversible treatment that relieves chronic nausea and vomiting and improves quality of life for patients when other treatments have failed.

About Enterra Medical

Simplify's Rating
Why Enterra Medical is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Healthcare

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Minneapolis, Minnesota

Founded

2022

Get referred to Enterra Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Medicare covered Enterra GES in ASC settings starting January 1, 2026.
  • ReliaStim and MRI labeling lower surgeon friction and expand eligible patient workflows.
  • NAVIGATE targets chronic nausea with normal gastric emptying, opening a larger market.

What critics are saying

  • FDA still says Enterra’s effectiveness is not demonstrated under HDE authorization.
  • Indication stays narrow: diabetic or idiopathic gastroparesis, ages 18 to 70 only.
  • If NAVIGATE and reimbursement expansion stall, larger neuromodulation rivals can crowd out adoption.

What makes Enterra Medical unique

  • Enterra ReliaStim launched January 12, 2026, improving GES lead placement precision.
  • Enterra II gained FDA MR Conditional approval in 2025, easing MRI access.
  • Enterra Therapy remains the only FDA-authorized GES option for drug-refractory gastroparesis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Recently Posted Jobs

Sign up to get curated job recommendations

Enterra Medical is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →